


(51) International Patent Classification:
C07H 19/14 (2006.01) A61K 31/7052 (2006.01)(21) International Application Number:
PCT/US2024/013021(22) International Filing Date:
26 January 2024 (26.01.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/482,133 30 January 2023 (30.01.2023) US
63/607,595 08 December 2023 (08.12.2023) US(71) Applicant: **MERCK SHARP & DOHME LLC** [US/US];
126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).(72) Inventors: **EMBREY, Mark W.**; 770 Summeytown Pike,
West Point, Pennsylvania 19486 (US). **LAYTON, Mark E.**; 770 Summeytown Pike, West Point, Pennsylvania 19486
(US). **RAHEEM, Izzat T.**; 770 Summeytown Pike, West
Point, Pennsylvania 19486 (US). **GROBLER, Jay A.**; 1438
Vestra Road, Gwynedd, Pennsylvania 19438 (US).(74) Agent: **GREENWALD, Eric**; 126 East Lincoln Avenue,
Rahway, New Jersey 07065 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS



(57) Abstract: The present invention is directed to prodrugs of compound A: which are nucleoside reverse transcriptase translocation inhibitors (NRTTI) and are useful in the inhibition of HIV reverse transcriptase. The present invention also relates to the use of these compounds for prophylaxis of infection by HIV, treatment of infection by HIV, and prophylaxis, treatment, and delay in the onset or progression of AIDS and/or AIDS-related complexes.




FIG. 2

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

10 October 2024 (10.10.2024)